Late Life Depression Clinical Trial
Official title:
A Breathing-Based Meditation Intervention for Patients With Treatment-Resistant Late Life Depression (TR-LLD): A Phase II Trial and Feasibility Study
Verified date | June 2018 |
Source | Lawson Health Research Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Late-life depression affects 2-8% of seniors and causes high rates of caregiver distress and
risk of suicide. To exacerbate the problem, antidepressants, the cornerstone of therapy, are
resistant in 55-80% of this population. Hence, this group of patients is labeled as having
treatment-resistant late-life depression (TR-LLD).
Non-pharmacological interventions like meditation could offer significant benefits as
augmentation strategies to improve response rate of antidepressants in TR-LLD. One such
breath-based meditation intervention called Sudarshan Kriya Yoga is of interest based on
highly significant preliminary data in adult patients with treatment-resistant depression,
its scalability and relatively low cost to learn this lifelong skill.
Thirty patients diagnosed with TR-LLD will learn this intervention over 5 consecutive days by
a certified para-professional trainer. This will be followed by 3 weekly 90 min follow-up
sessions and then bimonthly sessions for 8 more weeks. SKY consists of a series of breathing
techniques, including Sudarshan Kriya (SK), a sequential rhythm-specific breathing exercise.
Participants will be asked to practice this technique for 25-30 minutes daily over the next
11 weeks. The investigators will collect clinical as well as feasibility outcome measures.
The investigators will also explore if it is feasible to assess the antioxidant Glutathione
(GSH) in the brain using a sophisticated magnetic resonance spectroscopy. The investigators
suspect that GSH levels are reduced in TR-LLD and they will improve with SKY.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 60 Years to 80 Years |
Eligibility |
Inclusion Criteria: - 60-80 years of age - major depressive disorder, as per the results of an interview by a trained rater using the Structured Clinical Interview for DSM-5 and subsequently confirmed by the psychiatrist - Mild to moderate depression as confirmed by a score on the HAM-D 17 between 8 and 23 - Have failed at least two trials of antidepressants, given at adequate doses for adequate duration during the current episode - Able to follow verbal instructions and sit without physical discomfort for 45 minutes - Willing and able to attend at least 75% of all Sudarshan Kriya Yoga (SKY) sessions - Willing to dedicate 25-30 minutes/day to SKY practice at home - Low risk of suicide based on a clinical initial interview and during follow-up interviews at weeks 4, 8 and 12. Exclusion Criteria: - Uncontrolled hypertension, seizure disorder, psychosis, substance abuse, or dementia - Currently participating in other similar studies or currently practicing any type of formal meditation, mindfulness or breathing techniques - A major surgery within 6 weeks prior to commencement of or scheduled during, the study intervention - A traumatic brain injury - Any contraindications to MRI will also be excluded - Healthy control participants must have no significant mental health issues, or contraindications to MRI. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Lawson Health Research Institute |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Severity of TR-LLD as measured by the Hamilton Depression Scale (HAM-D17). | The primary outcome measure will be the Hamilton Depression Rating Scale (HAM-D 17) score. The HAM-D17 rates symptoms commonly associated with Major Depressive Disorder (MDD). A total score is calculated based on the first 17 questions of the HAM-D with a score range of 0 to 53. A higher score indicates more severe depression, and a lower score indicates fewer and/or less severe symptoms of depression. | 12 weeks | |
Secondary | Glutathione levels measured by a 7-Tesla Magnetic Resonance Imaging (7T-MRI) in TR-LLD. | Brain glutathione (GSH) levels, a measure of inflammatory stress, will be measured in the prefrontal cortex at baseline and after 12-weeks of SKY intervention via sophisticated magnetic resonance spectroscopy for TR-LLD. Control participants will complete one such measurement. | 12 weeks | |
Secondary | Caregiver burden in caregivers of TR-LLD as measured by the Zaritz Caregiver Burden scale. | The Zaritz Caregiver Burden scale will be administered to caregivers of TR-LLD participants. This scale indicates the burden placed on caregivers by providing care for TR-LLD patients. A total score will be calculated, with scores ranging from 0 to 88. A lower score indicates little to no burden while a higher score indicates severe burden. | 12 weeks | |
Secondary | Quality of Life of TR-LLD participants using the European Quality of Life (EQ-5D-5L) scale. | The European Quality of Life (EQ-5D-5L) scale will be used to assess the quality of life of study participants. This scale has two scores; the descriptive system and the EQ Visual Analogue scale (EQ VAS). The descriptive system consists of 5 questions each with 5 possible answers allowing for 5 possible health states. A score of 1 indicates no problems with the 5 measured dimensions, while a score of 5 would indicate the most severe possible state for each dimension. The descriptive system includes 5 sub-scores ranging from 1 (no issues) to 5 (severe problems), which will be converted to a specific single index value. The EQ VAS consists of only one question ranging from 0 (worst possible state of health) to 100 (best possible state of health). | 12 weeks | |
Secondary | Anxiety severity of TR-LLD participants measured by the Geriatric Anxiety Inventory (GAI). | The Geriatric Anxiety Inventory (GAI) assesses anxiety in geriatric patients. The questionnaire consists of 20 agree or disagree questions with total scores ranging from 0 (no anxiety) to 20 (severe anxiety). | 12 weeks. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05972798 -
Exploration of the Potential Mechanisms of n-3 Fatty Acids Supplementation in Depression and Cognitive Function in Patients With Late-life Depression
|
N/A | |
Completed |
NCT04504175 -
Ketamine for Older Adults Pilot
|
Phase 4 | |
Recruiting |
NCT05010915 -
TBS,TMS, Suicidal Ideation, Magnetic Resonance Imaging, Dorsolateral Prefrontal Cortex, Ventrolateral Prefrontal Cortex
|
N/A | |
Recruiting |
NCT06447428 -
One-Year Trajectory of Cognitive Changes in Patients With Late-life Depression in the Short Term
|
||
Completed |
NCT02960763 -
Optimizing Outcomes of Treatment-Resistant Depression in Older Adults
|
Phase 4 | |
Recruiting |
NCT04469959 -
Dopaminergic Dysfunction in Late-Life Depression
|
Phase 2 | |
Completed |
NCT03408821 -
CM Delivered PST in LLD Pilot
|
Phase 1 | |
Withdrawn |
NCT04887350 -
SSIPP vs. PST vs. WLC
|
Phase 1 | |
Completed |
NCT01908673 -
Automatic Self Transcending Meditation (ASTM) Versus Heart Rate Variability (HRV) Biofeedback in Patients With Late Life Depression (LLD): a Longitudinal Pilot Feasibility Study
|
N/A | |
Recruiting |
NCT05620511 -
Explore the Neural Mechanism of Mindfulness Training to Reduce Loneliness in Depressed Older Adults
|
N/A | |
Active, not recruiting |
NCT05531591 -
RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)
|
Phase 4 |